uniQure N.V.
0 products tracked · names used in filings: uniQure N.V.
Upcoming milestones
AMT-130: PDUFA target action date (Huntington's disease)
uniQure N.V. (QURE); ifezuntirgene inilparvovec; BLA; status: set; "uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S."; filed 2026-11-04 · source
ifezuntirgene inilparvovec: PDUFA target action date (Huntington's disease)
uniQure N.V. (QURE); ifezuntirgene inilparvovec; BLA; status: set; "The application has been granted Priority Review with a Prescription Drug User Fee Act (“ PDUFA ”) target action date of May 1, 2027."; filed 2026-11-02 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.